High hopes as Inventiva takes NASH contender into phase 3
pharmaphorum
JANUARY 6, 2021
The trial will take a while however, with results not due until the second half of 2023, with sales forecast to peak at around $2.6 A host of other pharma companies including Gilead, Novo Nordisk, Merck & Co are also developing potential NASH drugs. billion annually if approved.
52 
Let's personalize your content